Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling

Future Lipidology

Volumn 3, Issue 6, 2008, Pages 697-704

  Planaguma, Anna ^a   Levy, Bruce D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Analogs; Asthma; Inflammation; Lipoxins; Mediators; Resolution

Indexed keywords

3 OXA LIPOXIN A4 DERIVATIVE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CD59 ANTIGEN; CORTICOSTEROID; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; FORMYLPEPTIDE RECEPTOR LIKE 1; ICOSAPENTAENOIC ACID; LIPOXIN; LIPOXIN A4 DERIVATIVE; OMEGA 3 FATTY ACID; RESOLVIN; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; DRUG HYPERSENSITIVITY; EXERCISE INDUCED ASTHMA; FATTY ACID METABOLISM; GENE EXPRESSION REGULATION; HUMAN; LUNG DISEASE; NONHUMAN; OXIDATION REDUCTION STATE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 67149096166     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.6.697     Document Type: Review

References (44)

1. Weiss U: Inflammation. Nature 454(7203), 427 (2008).
2. Busse WW, Lemanske RF Jr: Asthma. N. Engl. J. Med. 344(5), 350-362 (2001).
3. Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 454(7203), 445-454 (2008).
4. Barnes JP: New drugs for asthma. Nat. Rev. Drug Discov. 3(10), 831-844 (2004).
5. Moore WC, Bleecker ER, Curran-Everett E et al.: Characterization of the severe asthma phenotype by the National Heart, Lung, Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 119(2), 405-413 (2007).
6. Wenzel SE, Szefler SJ, Leung DY et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 156(3 Pt 1), 737-743 (1997).
7. Fahy JV, Kim KW, Liu J, Boushey HA: Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 95 (4), 843-852 (1995).
8. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, biological effects. Science 237(4819), 1171-1176 (1987).
9. Serhan NC: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137 (2007)
10. 4 and its relationship to the sulfidopeptide leukotrienes C4, D4, E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Respir. Dis. 141(6), 1453-1458 (1990).
11. Parameswaran K, Radford K, Fanat A et al.: Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. Am. J. Respir. Cell Mol. Biol. 37(2), 240-247 (2007).
12. 4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 145(6), 1281-1284 (1992).
13. Drazen JM, Israel E, O'Byrne MO: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340(3), 197-206 (1999).
14. Levy BD, Bonnans C, Silverman ES, Palmer J, Marigowda G, Israel E: Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172(7), 824-830 (2005).
15. 4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178(6), 574-582 (2008).
16. Mayadas TN, Mendrick DL, Brady HR et al.: Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 49(5), 1342-1349 (1996).
17. Wittwer J, Bayer M, Mosandl A, Muntwyler J, Hersberger M: The c.-292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective. Clin. Chem. Lab. Med. 45(4), 487-492 (2007).
18. Serhan CN, Jain A, Marleau S et al.: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171(12), 6856-6865 (2003).
19. Fiore S, Serhan CN: Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 172(5), 1451-1457 (1990).
20. Kuhn H, Heydeck D, Brinckman R, Trebus F: Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, post-translational levels. Lipids 34(Suppl.), S273-S279 (1999).
21. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD: Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174(8), 5033-5039 (2005).
22. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2(7), 612-6.19 (2001).
23. Zhang MZ, Harris RC, McKanna JA: Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc. Natl Acad. Sci. USA 96(26), 15280-15285 (1999).
24. Vachier I, Bonnans C, Chavis C et al.: Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol. 115(1), 55-60 (2005).
25. Sanak M, Levy BD, Clish CB et al.: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16(1), 44-49 (2000).
26. 4 in exercise-induced bronchoconstriction in asthma. J. Asthma 45(2), 161-164 (2008).
27. 4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin. Exp. Allergy 37(10), 1494-1501 (2007).
28. Karp CL, Flick LM, Park KW et al.: Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5 (4), 388-392 (2004).
29. Kowal-Bielecka O, Kowal K, Distler O et al.: Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and anti-inflammatory lipid mediators. Arthritis Rheum. 52(12), 3783-3791 (2005).
30. Kowal-Bielecka O, Distler O, Kowal K et al.: Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum. 48(6), 1639-1646 (2003).
31. Schwartz J, Weiss ST: The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I). Eur. Respir. J. 7(10), 1821-1824 (1994).
32. 4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9(8), 873-879 (2008).
33. Levy BD, Kohli P, Gotlinger K et al.: Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol. 178(1), 496-502 (2007).
34. 4. Nat. Med. 8(9), 1018-1023 (2002).
35. 4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. 21(14), 3877-3884 (2007).
36. 4 regulates bronchial epithelial cell responses to acid injury. Am. J. Pathol. 168(4), 1064-1072 (2006).
37. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146), 869-874 (2007).
38. Chiang N, Serhan CN, Dahlen SE et al.: The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58(3), 463-487 (2006).
39. 4 receptor that is regulated by interleukin (IL)-13 and interferon γ and inhibits tumor necrosis factor α-induced IL-8 release. J. Exp. Med. 187(8), 1285-1294 (1998).
40. Petasis NA, Akritopoulou-Zanze I, Fokin VV et al.: Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73(3-4), 301-321 (2005).
41. 4 analogs. Prostaglandins Leukot. Essent. Fatty Acids 73 (3-4), 245-250 (2005).
42. Canny G, Levy O, Furuta GT et al.: Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl Acad. Sci. USA 99(6), 3902-3907 (2002).
43. Machado FS, Esper L, Dias A et al.: Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J. Exp. Med. 205(5), 1077-1086 (2008).
44. Machado FS, Johndrow JE, Esper L et al.: Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12(3), 330-334 (2006).